Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123062) titled 'Efficacy and Predictive Factors of Vunakizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis' on April 21.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Shanghai Skin Hospital

Condition: Plaque Psoriasis

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2025-03-04

Target Sample Size: The group treated with nivolumab:200;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=298818

Disclaimer: Curated by HT Syndication....